NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

learningcurve2020,

Thank you for posting the article that links to JCI! I think that PD1 blockade technology in combo with the DCVax-L cell-based platform technology will reshape the field of immunotherapy in oncology! It will be exciting to see more clinical data following the recent release of interim results from the UCLA pembrolizumab DCVax-L combo study!

https://www.jci.org/articles/view/169314


Targeted individualized combo therapies are emerging as the defining feature of a new era of oncology. Just look at the impact that PD1 blockade technology has had on the field of oncology in recent years!


https://www.fda.gov/drugs/news-events-human-drugs/50-years-progress-treating-patients-cancer

The P3 study of the DCVax-L cell-based platform technology is a landmark trial.

The P3 data were peer reviewed by independent physicians and qualified statisticians—please refer to JAMA Oncology. You might consider researching credible full-context sources to gather reliable information.

The DCVax-L cell-based technology has been under clinical investigation for a significant period of time, and the overall clinical data in total include three trials spanning many years. Safety and efficacy data have been gathered from trials with external controls and trials with placebo controls. The data include DCVax-L as a monotherapy and in combination with other agents.

The interim PD1 combo data are brilliant, and the trial is significant for a number of reasons relating to FDA guidelines and NIH peer-reviewed grant funding.



https://clinicaltrials.gov/ct2/show/NCT04201873

https://www.fda.gov/media/120721/download

In the combo trial, patients who receive DCVax-L + placebo are being compared to patients who receive DCVax-L + pembrolizumab.

The control arm is receiving DCVax-L. While DCVax-L is not the current SOC, it is highly significant and notable that DCVax-L is being permitted to fill the role of SOC as the best available therapy within this combo study for rGBM. The combo trial also follows the P3 in sequence which in itself validates the findings of the P3 study—the placebo group in the PD1 study would not be receiving DCVax-L today if the preceding P3 trial had not proven its efficacy.



https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers